Gland Pharma Revenue History — Quarter by Quarter

Gland Pharma's revenue moved from ₹1,209 Cr in Q1 FY24 to ₹1,743 Cr in Q4 FY26, a 44.2% change over 12 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q4 FY26	₹1,743 Cr	+22%
Q3 FY26	₹1,695 Cr	+22%
Q2 FY26	₹1,487 Cr	+6%
Q1 FY26	₹1,506 Cr	+7%
Q4 FY25	₹1,425 Cr	—
Q3 FY25	₹1,384 Cr	—
Q2 FY25	₹1,406 Cr	+2%
Q1 FY25	₹1,407 Cr	+16%
Q4 FY24	₹1,537 Cr	+19%
Q3 FY24	₹1,545 Cr	+65%
Q2 FY24	₹1,373 Cr	+32%
Q1 FY24	₹1,209 Cr	+41%

What management said about revenue

Q4 FY26 · FY27 consolidated revenue growth of 12-13% constant currency

Management expects 12-13% revenue growth in FY27 on constant currency basis, excluding GLP-1 upside.

Q3 FY26 · FY27 organic growth of 12-13%

Management expects base business to grow 12-13% in FY27, with potential upside from European CMS approvals and Dalbavancin launch.

Q3 FY26 · Five-year organic CAGR of 15%

Company targets 15% organic CAGR over five years, excluding inorganic contributions, driven by capacity expansions and CDMO contracts.

Q3 FY26 · Cenexi annualized revenue run-rate of EUR 200M

Cenexi expected to maintain EUR 50 million quarterly run-rate on an annualized basis, with positive EBITDA trajectory.

Q2 FY26 · Mid-teens consolidated revenue growth for FY26

Management reaffirmed mid-teens revenue growth guidance for FY26, driven by new launches (dalbavancin, colistimethate) and Cenexi improvement.

Q2 FY26 · Cenexi break-even in Q3 FY26

Cenexi is expected to break even in Q3 FY26, supported by EUR 50 million quarterly revenue target and cost initiatives.

Q1 FY26 · Mid-teen overall revenue growth for FY26

Management reiterated guidance for mid-teen consolidated revenue growth for the full year, driven by U.S. launches and Cenexi recovery.

Q1 FY26 · 20 million GLP-1 units commercialization in FY27

Management expects to commercialize around 20 million pens/cartridges in FY27, primarily for RoW markets.

Q4 FY25 · Mid-teens consolidated revenue growth in FY26

Management expects consolidated revenue to grow in the mid-teens percentage range in FY26, driven by new launches, CMO projects, and biologics.

Q4 FY25 · Biologics revenue of INR 100 crore in FY26

The biologics segment, including the Dr. Reddy's collaboration, is expected to contribute approximately INR 100 crore in revenue in FY26.

Q3 FY25 · Cenexi revenue run rate of EUR 15M per quarter

Management targets Cenexi quarterly revenue above EUR 15 million to support EBITDA breakeven, driven by new high-speed lines.

Q3 FY25 · Biologics CDMO revenue from Dr. Reddy's from FY26

Collaboration with Dr. Reddy's for biologics CDMO is expected to generate incremental revenue starting next financial year (FY26).